BeyondSpring Inc. (BYSI): Cash & Equivalents
$7.79M
As of 2025-12-31
$2.70M
As of 2026-06-30
-39.1%
3-year compound annual growth
-41.1%
5-year compound annual growth
-3.2%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.79M | +166.5% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $2.92M | -45.8% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $5.40M | -84.3% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $34.40M | -17.4% | 2023-04-18, Balance as of period end |
| 2021-12-31 | $41.62M | -62.0% | 2023-04-18, Balance as of period end |
| 2020-12-31 | $109.54M | +204.8% | 2022-04-14, Balance as of period end |
| 2019-12-31 | $35.93M | +824.0% | 2021-04-30, Balance as of period end |
| 2018-12-31 | $3.89M | -85.8% | 2020-04-30, Balance as of period end |
| 2017-12-31 | $27.48M | +135.1% | 2020-04-30, Balance as of period end |
| 2016-12-31 | $11.69M | +8.0% | 2019-04-30, Balance as of period end |
| 2015-12-31 | $10.82M | n/m | 2018-04-03, Balance as of period end |
| 2014-12-31 | $392.0K | n/a | 2017-04-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| BeyondSpring Inc. (BYSI) | 2025-12-31 | $7.79M | +166.5% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare BYSI, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗